Rheumatology Advance Access published online on November 15, 2005
Rheumatology, doi:10.1093/rheumatology/kei090
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Immunology and Institute of Infection, Immunity and Inflammation, School of Molecular Medical Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, UK
* To whom correspondence should be addressed. Objective. To investigate the levels of the pro-inflammatory cytokines IL-6, TNF- Methods. Cytokine concentrations were measured in sequential plasma samples obtained from eight patients with a C33Y mutation in TNFRSF1A and diagnosed with TRAPS, using cytokine bead array. The TRAPS samples were compared with samples from normal controls and rheumatoid arthritis patients. Results. Levels of IL-6 were significantly elevated in C33Y TRAPS patients and these correlated with CRP levels in some of the patients. IL-8 levels were also significantly elevated in the TRAPS patients. However, neither TNF- Conclusions. The cytokine profile of C33Y TRAPS differs from that of a typical autoimmune inflammatory condition such as rheumatoid arthritis, as only IL-6 and IL-8 were elevated in C33Y TRAPS patients, as distinct from a generalized elevation of pro-inflammatory cytokines. However, only some of the C33Y patients tested showed a relationship between elevated IL-6 and CRP. This is consistent with clinical observations that there is marked heterogeneity between individuals with TRAPS, including those in the same family cohort. Although etanercept has a therapeutic effect in some TRAPS patients, it induces increased plasma concentrations of TNF-
Received March 17, 2005
Accepted August 1, 2005
Original Papers
Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A
M. L. Nowlan 1,
E. Drewe 1,
H. Bulsara 1,
N. Esposito 1,
R. A. Robins 1,
P. J. Tighe 1,
R. J. Powell 1,
and
I. Todd 1 *
I. Todd, E-mail: ian.todd{at}nottingham.ac.uk
Abstract 
, IL-1
, IL-8, IL-10 and IL-12p70 in the plasma of patients with TNF receptor-associated periodic syndrome (TRAPS) in relation to CRP levels and treatment with etanercept. nor IL-1 demonstrated a similar increase. This differed from the patients with rheumatoid arthritis, for whom levels of IL-6, IL-8, TNF-, IL-1 and IL-10 were significantly elevated. The levels of detectable TNF- in the TRAPS patients’ plasma were elevated during etanercept treatment., possibly by increasing TNF- stability.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Jacobelli, M. Andre, J.-F. Alexandra, C. Dode, and T. Papo Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS) Rheumatology, July 1, 2007; 46(7): 1211 - 1212. [Full Text] [PDF]
|
|
|
|
|
|
H. Ida, T. Aramaki, K. Arima, T. Origuchi, A. Kawakami, and K. Eguchi Successful treatment using tacrolimus (FK506) in a patient with TNF receptor-associated periodic syndrome (TRAPS) complicated by monocytic fasciitis Rheumatology, September 1, 2006; 45(9): 1171 - 1173. [Full Text] [PDF]
|
|